Parenteral Cidofovir for Cytomegalovirus Retinitis in Patients with AIDS: The HPMPC Peripheral Cytomegalovirus Retinitis Trial: A Randomized, Controlled Trial
Annals of Internal MedicinePublished 15 February 1997
Citations180
SJR quartileQ1
SJR score3.38
SNIP3.27
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
The HPMPC Peripheral Cytomegalovirus Retinitis Trial (HPCRT) was a randomized, controlled clinical trial done to evaluate the efficacy and safety of intravenous cidofovir for the treatment of CMV retinitis in patients with AIDS.
Abstract
Intravenous cidofovir, high- or low-dose, effectively slowed the progression of CMV retinitis. Concomitant probenecid and hydration therapy, intermittent dosing, and monitoring for proteinuria seemed to minimize but not eliminate the risk for nephrotoxicity.
Keywords
Medicine